UPDATED: Long-awaited Novavax PhIII results show 90.3% overall efficacy, with 100% effectiveness against moderate and severe Covid-19
After several months of delays and setbacks, the small Maryland biotech Novavax has finally completed its North American Phase III trial for its Covid-19 vaccine. And though they say the topline results are positive, it remains to be seen how much uptake there will be in the US given the waning numbers of cases, rising vaccination rates and a surplus of already-authorized vaccines.
Overall efficacy in the study hit 90.3% across nearly 30,000 patients in the US and Mexico, Novavax said, with a total of 77 cases observed. In the placebo arm, researchers saw 63 cases of Covid-19 compared to 14 in the vaccine group. Participants were randomized into the vaccine arm 2 to 1, and Novavax said it collected its data between Jan. 25 and April 30.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.